Related Experiment Video
Updated: Jun 3, 2026
07:54
Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
Published on: December 21, 2019
Chemotherapy for malignant pleural mesothelioma
1Arizona Cancer Center, University of Arizona College of Medicine, Tucson, AZ 85724, USA. LGarland@azcc.arizona.edu
Current Treatment Options in Oncology
|April 7, 2011
Summary
For malignant pleural mesothelioma (MPM) patients with good performance status, clinical trials are recommended. Standard frontline therapy for fit MPM patients is an antifolate/platinum doublet, offering survival and quality of life benefits.
Area of Science:
- Oncology
- Thoracic Oncology
- Mesothelioma Research
Background:
- Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer.
- Treatment decisions for MPM depend on patient performance status and prior therapies.
- Optimizing chemotherapy regimens is crucial for improving outcomes in MPM.
Purpose of the Study:
- To provide an opinion statement on the optimal management of malignant pleural mesothelioma.
- To guide the selection of frontline and second-line chemotherapy for MPM patients.
- To emphasize the role of clinical trials and prognostic scales in MPM treatment.
Main Methods:
- Review of existing clinical trial data and established treatment guidelines for MPM.
- Analysis of survival benefits and quality of life improvements associated with different chemotherapy regimens.
- Consideration of prognostic scales (CALGB and EORTC) for patient stratification.
Main Results:
- Antifolate/platinum doublet chemotherapy is the standard frontline treatment for fit MPM patients, demonstrating survival and quality of life benefits.
- Single agents are appropriate for less fit MPM patients as frontline therapy.
- Retreatment with pemetrexed or other agents/combinations can be beneficial in the second-line setting for fit patients with adequate progression time.
Conclusions:
- Clinical trial enrollment should be considered for all fit MPM patients.
- Treatment selection should be tailored based on performance status, prior treatment, and time to progression.
- Prognostic scales aid in selecting appropriate frontline and second-line chemotherapy for MPM.
More Related Videos
Related Concept Videos
01:30Pleural Disorders: Types and Brief Description
The pleura is a vital part of the respiratory system. It's a double-layered membrane surrounding the lungs and lining the chest cavity. The two layers of the pleura are:
01:28Pleural Effusion II: Symptoms and Management
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...